RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients. ...

Core Insights - Merck and Eisai announced that their combination therapy WELIREG® plus LENVIMA® met the primary endpoint of progression-free survival (PFS) in certain previously treated patients with advanced renal cell carcinoma [1] Group 1 - The combination therapy demonstrated significant efficacy in improving PFS for patients with advanced renal cell carcinoma [1] - This development highlights the ongoing collaboration between Merck and Eisai in the oncology sector [1] - The results may lead to further advancements in treatment options for patients with this type of cancer [1]